AgingResearch.NewsJoin free

Tolerance Bio

CompanyUnited States

Tolerance Bio develops 2 assets, the furthest in phase 1 (Efineptakin alfa in thymic function). Mostly protein or enzyme and antibody acting on IL7R and IL33; based in the United States.

2
Assets
Furthest stage
Phase 1
Raised
US$47.4m
0
Trials
0
Signals

Pipeline

2

  • Efineptakin alfa

    Long-acting interleukin-7 therapy intended to restore thymic function.

    Phase 1, Protein or enzyme, IL7R, thymic function

  • TLB-33

    Binds and neutralizes IL-33 to potentially preserve thymic function and enhance immune resilience.

    Human trials, Antibody, IL33, thymic preservation

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms2
  • Funding rounds and grants3
  • People13
  • Signals4
  • Similar companies6

Intelligence